{"id":"pregabalin-plus-bbcet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Somnolence"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pregabalin's mechanism of action is thought to involve the modulation of voltage-gated calcium channels, which reduces the release of excitatory neurotransmitters such as glutamate. This leads to a decrease in neuronal excitability and a reduction in the transmission of pain signals. BBCET's mechanism of action is complex, involving the partial agonism of opioid receptors by buprenorphine and the inhibition of dopamine and norepinephrine reuptake by bupropion.","oneSentence":"Pregabalin is an anticonvulsant and analgesic drug that modulates voltage-gated calcium channels, reducing excitatory neurotransmitter release. BBCET is a combination of Bupropion, an antidepressant, and buprenorphine, an opioid partial agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:05.350Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain, Major depressive disorder, Opioid use disorder"}]},"trialDetails":[{"nctId":"NCT02884908","phase":"PHASE3","title":"Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-07-07","conditions":"PTSD, Alcohol Use Disorder","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lyrica"],"phase":"phase_3","status":"active","brandName":"Pregabalin plus BBCET","genericName":"Pregabalin plus BBCET","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pregabalin is an anticonvulsant and analgesic drug that modulates voltage-gated calcium channels, reducing excitatory neurotransmitter release. BBCET is a combination of Bupropion, an antidepressant, and buprenorphine, an opioid partial agonist. Used for Chronic pain, Major depressive disorder, Opioid use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}